National Institute on Deafness and Other Communication Disorders (NIDCD)
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs by Stage
Trial / Program Status
Modality Mix
Indication Coverage
Program Types
Population Tags
Strong-Evidence Records
0 recordsChecked Records With Caveats
9 checked · 0 open checksOral ORC-13661 small molecule evaluated in a randomized Phase 2 dose-ranging trial to prevent or mitigate IV amikacin-associated ototoxic hearing loss in adults with nontuberculous mycobacterial disease.
Completed multicenter Phase 3 non-inferiority trial comparing intratympanic methylprednisolone sodium succinate injections with oral prednisone for idiopathic sudden sensorineural hearing loss.
Oral micronutrient combination of beta-carotene, vitamins C and E, and magnesium tested for prevention of temporary music-induced threshold shifts/noise-induced hearing changes.
Randomized double-blind trial evaluating gabapentin for relief of idiopathic subjective tinnitus.
Investigator-led Phase 1/2 studies of subcutaneous anakinra/Kineret in corticosteroid-resistant autoimmune inner ear disease and sudden sensorineural hearing loss.
Oral atorvastatin 40 mg daily during and after cisplatin-based chemoradiation, evaluated for reduction of cisplatin-induced hearing loss in adults with head and neck squamous cell carcinoma.
Observational age-related hearing study that captured hormone replacement therapy exposure while evaluating neural and psychoacoustic changes in the aging auditory system.
Terminated Phase 3 NIDCD study involving corticosteroids and methotrexate in sensorineural hearing loss associated with autoimmune inner ear disease.
Oral valganciclovir, a ganciclovir prodrug antiviral, evaluated to suppress congenital cytomegalovirus replication and reduce or stabilize CMV-associated sensorineural hearing-loss progression in infants and young children.